archive_header_en_20251203154432269.png

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

A password that applicants have been notified of is required to view abstracts.<br>If you are a participant and need to confirm the password, please contact us by e-mail about which annual meeting you would like to know the password for to view abstracts.<br>We will reply after confirming that you were a participant.<br>Thank you for your understanding.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Program Type

Identification and development of novel compounds inhibitory to SARS-CoV-2 replication

COVID-19, a new coronavirus infection that occurred at the end of 2019 caused a global pandemic, and the infection is still spreading all over the world. In order to overcome this serious infectious disease, it is indispensable to develop therapeutic drugs that target the causative virus SARS-CoV-2 or host-side factors involved in the aggravation of pneumonia. Therefore, Division of Medicinal Chemistry (DMC) will be in charge of this Japan-Korea joint symposium held once every two years at the annual meeting of the Pharmaceutical Society of Japan (PSJ). DMC is the largest division in PSJ, which deals with drug discovery including industry, government and academia. In this symposium, under the theme of “MedChemCorona: COVID-19 Frontiers in Drug Discovery Research”, we will introduce the scientific advance of both countries for drug discovery to solve this important issue. Four speakers from both countries who are conducting the cutting-edge drug discovery related to COVID-19 and viral infection will give lectures. We hope that the symposium will be a wonderful opportunity to discuss how pharmaceutical science should work toward the drug development for solving this important issue of COVID-19. We are looking forward to your participation.

The Pharmaceutical Society of Japan

The 141st Annual Meeting of the Pharmaceutical Society of Japan (Hiroshima)

The 141st Annual Meeting of the Pharmaceutical Society of Japan (Hiroshima)

[IS02-4]Identification and development of novel compounds inhibitory to SARS-CoV-2 replication

Password required to view